GlassScriptPhysician profile
Rachel Werner
NPI 1831642073
$12,082.00
in general payments reported to CMS, 2019-2025
29 companies · $3,000 in 2025
The $3,000 reported for 2025 was more than what 97% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,771 · 2022: $3,275 · 2023: $727 · 2024: $2,309 · 2025: $3,000.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,762 · Education: $274.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,761.59 |
| Education | $274.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,423.12 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $1,181.34 | 2021-2025 | |
| Revance Therapeutics, INC. | $1,043.46 | 2024-2025 | Daxxify, Daxi |
| Sun Pharmaceutical Industries INC. | $998.04 | 2021-2025 | Ilumya |
| Regeneron Healthcare Solutions, INC. | $715.13 | 2021-2025 | Dupixent |
| Janssen Biotech, INC. | $680.07 | 2021-2025 | Tremfya, Simponi, Simponi Aria |
| Mayne Pharma Commercial LLC | $585.73 | 2021-2025 | |
| Lilly USA, LLC | $567.38 | 2021-2025 | Taltz, Ebglyss, Olumiant |
| Amgen INC. | $525.56 | 2021-2025 | Otezla, Otezla |
| Galderma Laboratories, L.P. | $472.33 | 2021-2025 | Nemluvio, Aklief |
| Journey Medical Corporation | $440.63 | 2021-2024 | |
| Incyte Corporation | $424.63 | 2021-2025 | Opzelura |
| Genzyme Corporation | $406.77 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $394.32 | 2022-2024 | Sotyktu |
| Arcutis Biotherapeutics, INC. | $319.70 | 2024-2025 | Zoryve |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $302.53 | 2024 | Vtama |
| Pfizer INC. | $255.78 | 2021-2025 | |
| Leo Pharma INC. | $221.44 | 2021-2025 | Adbry, Anzupgo |
| Almirall LLC | $197.52 | 2021-2024 | Seysara |
| Ucb, INC. | $164.57 | 2022-2025 | Bimzelx |
| Vyne Pharmaceuticals INC. | $156.79 | 2021 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $146.66 | 2021-2025 | Jublia, Cabtreo, Arazlo |
| Organon LLC | $121.68 | 2025 | Vtama |
| Janssen Scientific Affairs, LLC | $109.61 | 2021 | |
| Epi Health, LLC | $98.76 | 2021-2022 | |
| Botanix Sb INC | $56.76 | 2025 | Sofdra |
| Allergan, INC. | $30.08 | 2021 | |
| Verrica Pharmaceuticals INC. | $22.48 | 2024 | Ycanth |
| Mission Pharmacal Company | $19.13 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rachel Werner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.